Dupixent, Flu Vaccine Demand Boost Sanofi's Q3 Earnings, Lifts Annual Outlook

Dupixent, Flu Vaccine Demand Boost Sanofi's Q3 Earnings, Lifts Annual Outlook
  • Sanofi SA SNY said it now expects 2022 adjusted earnings per share to grow by about 16%. The positive currency impact on 2022 business EPS is estimated at +9.5% to +10.5%. It had previously forecast growth of 15%.
  • The company reported Q3 sales of €12.48 billion, +19.7% Y/Y supported by the strong performance of specialty care driven by Dupixent, Flu vaccines, and core assets from General Medicines.
  • Dupixent sales increased 44.5% to €2.3 billion.
  • Related: Sanofi Ends Development Of Breast Cancer Drug Amcenestrant After Trial Failure.
  • It also reported a 26.5% rise in third-quarter business operating income, or adjusted earnings before interest and tax, to €4.5 billion.
  • Sanofi wrote off €1.56 billion, the value of the most advanced drug project of Synthorx that Sanofi agreed to acquire for $2.5 billion in 2019. 
  • Sales from influenza vaccines jumped by a currency-adjusted 32.4% to €1.99 billion, mainly driven by higher influenza vaccine sales.
  • Price Action: SNY shares closed 1.13% higher at $42.05 during after-hours trading on Thursday.

Posted In: BriefsEurasiaBiotechEarningsLarge CapNewsGuidanceHealth CareGeneral